Baxter International reported mixed Q4 2025 results with an 8% sales increase to $2.97 billion but a 24% decrease in adjusted diluted EPS from continuing operations, and a significant GAAP loss. The company also announced a board refresh, including a new appointment and two resignations, alongside guidance for roughly flat 2026 sales and lower adjusted EPS. An analyst maintains a Hold rating, while TipRanks’ AI Analyst Spark rates BAX as Neutral due to financial weakness and operational headwinds.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Baxter International Reports Mixed Q4 Results and Outlook
Baxter International reported mixed Q4 2025 results with an 8% sales increase to $2.97 billion but a 24% decrease in adjusted diluted EPS from continuing operations, and a significant GAAP loss. The company also announced a board refresh, including a new appointment and two resignations, alongside guidance for roughly flat 2026 sales and lower adjusted EPS. An analyst maintains a Hold rating, while TipRanks’ AI Analyst Spark rates BAX as Neutral due to financial weakness and operational headwinds.